Ezekowitz Alan 4
4 · Fulcrum Therapeutics, Inc. · Filed Jun 30, 2026
Research Summary
AI-generated summary of this filing
Fulcrum Therapeutics (FULC) Director Alan Ezekowitz Sells 18,000 Shares
What Happened
Alan Ezekowitz, a director of Fulcrum Therapeutics (FULC), sold 18,000 shares on June 26, 2026. The weighted average sale price was $3.65 per share, for total proceeds of approximately $65,614. This was a disposition (sale), not a purchase.
Key Details
- Transaction date: 2026-06-26; Form 4 filed: 2026-06-30 (filed within the required 2 business days).
- Shares sold: 18,000; weighted average price reported: $3.65; total proceeds: $65,614.
- Price range: shares were sold in multiple trades at prices from $3.555 to $3.82 (inclusive). The filer will provide a per-price breakdown on request.
- Reported as sale (Code S) via open market or private sale.
- The sales were effected under a Rule 10b5-1 trading plan adopted by Ezekowitz on March 27, 2026.
- Shares owned after the transaction: not disclosed in this Form 4 excerpt.
Context
A 10b5-1 plan allows insiders to execute pre-arranged trades and is commonly used to avoid questions about timing; transactions under such plans are generally considered routine and do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases by insiders often carry more weight as a bullish signal; recorded sales like this primarily show liquidity or routine portfolio management rather than an explicit vote on company prospects.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-06-26$3.65/sh−18,000$65,614→ 10,927 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.555 to $3.82, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.